Ireland-headquartered generic major Actavis (NYSE: ACT) has entered into an agreement with US pharma giant Pfizer (NYSE: PFE) to settle all outstanding patent litigation related to Actavis' generic version of Celebrex (celecoxib) capsules.
Under the terms of the agreement, Pfizer will grant Actavis a license to market its generic Celebrex beginning in December 2014, or earlier under certain circumstances. Other details of the settlement were not disclosed.
Launch of Actavis' product is contingent on the company receiving final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for a generic version of Celebrex.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze